Spinal muscular atrophy (SMA) is a rare, inherited neuromuscular disease caused by deletion and/or mutation of the Survival of Motor Neuron 1 (SMN1) gene. A second gene, SMN2, produces low levels of functional SMN protein that are insufficient to fully compensate for the lack of SMN1. Risdiplam (RG7916; RO7034067) is an orally administered, small-molecule SMN2 pre-mRNA splicing modifier that distributes into the central nervous system (CNS) and peripheral tissues. To further explore risdiplam distribution, we assessed in vitro characteristics and in vivo drug levels and effect of risdiplam on SMN protein expression in different tissues in animal models. Total drug levels were similar in plasma, muscle, and brain of mice (n = 90), rats (n = 148), and monkeys (n = 24). As expected mechanistically based on its high passive permeability and not being a human multidrug resistance protein 1 substrate, risdiplam CSF levels reflected free compound concentration in plasma in monkeys. Tissue distribution remained unchanged when monkeys received risdiplam once daily for 39 weeks. A parallel dose-dependent increase in SMN protein levels was seen in CNS and peripheral tissues in two SMA mouse models dosed with risdiplam. These in vitro and in vivo preclinical data strongly suggest that functional SMN protein increases seen in patients' blood following risdiplam treatment should reflect similar increases in functional SMN protein in the CNS, muscle, and other peripheral tissues.
The hallmark of SMA is the progressive degeneration of α-motor neurons in the brain stem and spinal cord that causes muscle atrophy, weakness, and disease-related complications that can impact survival. 5 Accumulating evidence challenges the idea that SMA is solely a disease of motor neurons. SMA is increasingly described as a disease affecting tissues and cell types beyond the motor neuron,
suggesting that effective disease intervention may require body-wide correction of SMN protein levels to achieve a complete reversal or amelioration of the disease state. [5] [6] [7] This is consistent with the requirement of peripheral SMN restoration for long-term rescue in a severe SMA animal model. [8] [9] [10] SMN protein is ubiquitously expressed throughout the body and is implicated in several basic cellular functions. 11 SMN protein may have a role in many cells and tissues, such as skeletal muscle, heart, bone, and autonomic and nervous systems; and deficiencies may contribute to the disease state. 5, 7, 12 A significant clinical benefit has been observed with therapies that increase levels of functional SMN protein. Recently, an antisense oligonucleotide therapy (nusinersen, Spinraza ® ), which is administered intrathecally, was approved in the U.S. and European Union for the treatment of SMA in pediatric and adult patients. Both Spinraza ® and risdiplam (having different molecular targets) act by promoting exon 7 inclusion in SMN2 mRNA, leading to increased production of functional SMN protein. [13] [14] [15] Approval of Spinraza ® as a treatment for SMA in adult and pediatric patients validated the mechanism of action and effectiveness of SMN2 mRNA-splicing therapies.
RG7800 was the first small molecule SMN2 splicing modifier to enter human clinical trials. 16 In the Phase 1 MOONFISH trial (NCT03032172) no serious adverse events were reported following RG7800 administration in patients with Type 2 and 3 SMA. However, dosing was suspended due to off-target retinal findings of RG7800 in long-term, nonclinical safety studies in monkeys.
Risdiplam is an orally administered, small-molecule SMN2 premRNA splicing modifier, optimized in terms of pharmacokinetic (PK) characteristics and with enhanced specificity toward SMN2 exon 7 splicing relative to other SMN2 splicing modifiers. 17 Risdiplam demonstrated a higher in vitro and in vivo efficacy in cellular and mouse models of SMA, a larger safety window in preclinical models (including to off-target retinal findings) and an improved human PK profile compared with RG7800. 17 Risdiplam increases SMN2FL mRNA production and distributes into the central nervous system 
| MATERIALS AND METHODS
Risdiplam structure and method of synthesis can be found in reference. 17 RG7800 structure and method of synthesis can be found in reference. The rodent Mdr1a is a murine protein and shares 95% amino acid sequence identity with the rat Mdr1a, 19 henceforth referred as "rodent" Mdr1a throughout the manuscript. The assays were conducted as previously described. 20, 21 Briefly, cells were cultured on semipermeable 96-well inserts (surface area 0.11 cm 2 , pore size 0.4 mm; Millipore), and bidirectional transport measurements were performed either at Day 3 or 4 after seeding. The medium was removed from the apical (100 mL) and basolateral (240 mL) compartments and replaced on the receiver side by culture medium without phenol red and with or without inhibitor (zosuquidar, 1 μM for L-MDR1 and L-Mdr1a; Ko143, 1 μM for M-BCRP and M-Bcrp). Transcellular transport was initiated by the addition of media to the donor compartment containing test substrate (risdiplam or RG7800, tested at 1 μM) and 10 μM Lucifer yellow (Sigma-Aldrich). Lucifer yellow was included to confirm monolayer integrity and reference substrates were incubated as controls to MDR1/Mdr1a or BCRP/Bcrp activity.
Plates were incubated for 3.5 hours at 37°C and 5% CO 2 under continuous shaking (100 rpm). Samples (triplicates for each condition) were taken from the donor and receiver compartments and analyzed by scintillation counting or high-performance liquid chromatography with tandem mass spectrometry, as previously described for liquid chromatography, 10ADvp pump system (Shimadzu, Kyoto, Japan) coupled with a PAL HTS auto-sampler (CTC Analytics, Zwingen, Switzerland) was used, and for MS, API 4000 or QTrap4000 system equipped with a TurboIonspray source (Sciex,
Framingham, MA).
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For data evaluation the following equations were used:
where P app , A, C 0 , and dQ/dt represent the apparent permeability, the filter surface area, the initial concentration, and the amount transported per time period, respectively. P app values were calculated on the basis of a single time point. Transport efflux ratios (ERs) were calculated as follows:
where P app BA is the permeability value in the basolateral-to-apical direction, and P app AB is the permeability value in the apical-to-basolateral direction.
| Animals
Thirteen animal studies were carried out as listed in Two different mouse models of SMA were utilized for these studies.
For studies in adult mice, the C/C-allele mouse model of mild SMA was utilized. C/C-allele mice have a near-normal life span but show decreased muscle function, reduced body weight gain, and peripheral necrosis in comparison to normal mice. 22 Neonatal SMNΔ7 mice, a mouse model of severe SMA, were also used. These mice die approximately 2 weeks after birth. For information on doses and length of dosing for each individual study, please see Table 1 .
After dosing, blood was collected by terminal cardiac puncture at In Study 5, dosing was initiated at PND3 IP at 0.3, 1, or 3 mg/kg/day and changed to PO dosing of 1, 3, or 10 mg/kg/day from PND24 onwards.
Discovery Sector Imager 6000 instrument as previously published. where γ is a fixed parameter (0.753) and ER the efflux ratio measured in L-Mdr1a cells.
| Study design in monkeys (Studies 9 and 10)
Risdiplam was administered orally by gavage once daily as a solution in 10 mM ascorbic acid/0.01 mg/mL sodium thiosulfate pentahydrate, pH 3, and the dosing volume was 1.5 mL/kg (Study 9) or 5 mL/kg (Study 10). For information on doses and length of dosing for each individual study, please see Table 1 .
At the end of dosing, animals were killed, and terminal plasma and tissues were collected and stored frozen. In Study 10, brain stem and cortex samples (0.5 g) were separately collected. A sample of 0.5 mL of CSF was collected from all animals.
Tissues were homogenized and diluted with blank cynomolgus monkey plasma. The analyte was isolated from matrix as described for Studies 6-8. Detection was accomplished utilizing HESI MS/MS in positive ion SRM. The LLOQ in cynomolgus monkey plasma was 0.250 ng/mL (Study 9) or 0.500 ng/mL (Study 10) using 20 μL aliquots. All other samples were quantified against cynomolgus monkey plasma calibration curves. Due to sample dilution, the resulting LLOQs were 0.500 ng/mL in CSF (Study 9) and between 0.500 and 5000 ng/g in tissues (10.0 ng/g in brain). For Study 10, a dedicated, sensitive CSF method with LLOQ 0.100 ng/mL was used. Unbound (free) plasma concentrations were calculated by multiplying the measured total concentration in plasma by the measured free fraction in plasma (15% in adult cynomolgus monkeys).
| Rat Quantitative Whole-Body

Autoradiography (QWBA) study design (Study 13)
Wistar rats received either a single oral dose of at the following times after dosing: 10 min for the IV-dosed animals and 2, 24, 72, and 168 hours for the oral-dosed animals. Once fully frozen, the carcasses were prepared for, and subjected to, wholebody autoradiography procedures. Radioactivity concentration in tissues was quantified from the whole-body autoradiograms, using a validated image analysis system. After exposure in a copper-lined, lead exposure box for 7 days, the imaging plates were processed using a FUJI FLA 5000 or 5100 radioluminography system (Raytek Scientific Ltd). The electronic images were analyzed using a validated PC-based image analysis package (Seescan2 software, LabLogic).
While under terminal anesthesia, blood (approximately 3 mL) was collected from each of the animals by cardiac puncture into tubes precoated with lithium heparin. Blood and plasma were assayed for total radioactivity.
| RESULTS
| Transport in vitro assays
Risdiplam showed an average passive permeability in parental LLC- RG7800 was also a highly permeable compound, with an average passive permeability in LLC-PK1 cells of ≥100 nm/s and was also not a substrate of human MDR1.
| Risdiplam tissue distribution
During the preclinical development of risdiplam, brain, and muscle tissues, as well as key organs affected in SMA, were collected as primary or secondary endpoints in a variety of PK, pharmacodynamics (PD), and toxicology studies. Single or repeat daily oral or IP administration of risdiplam for up to 39 weeks showed similar total drug levels in plasma, brain, and muscle of mice (n = 90), rats (n = 148), and monkeys (n = 24) ( Figure 1A,B) . CSF levels of risdiplam in monkeys reflected those of free, nonbound compound in plasma. A minor deviation from unity was observed in rat CSF levels compared with free plasma levels ( Figure 1C ) and in mice brain levels compared with total plasma ( Figure 1A ). The observed in vivo Kp,uu in rats was 0.28. Figure 1A .
In Study 10, tissue drug levels were maintained after daily dosing in monkeys receiving risdiplam daily for 39 weeks. At the end of the dosing period, some monkeys remained on study but no longer received the drug (recovery animals). Drug levels were below the limit of quantification (BLQ) in plasma, CSF, and brain after 22 weeks' treatment-free recovery period (muscle not sampled). In nonhuman primates, the ratios of total risdiplam concentration in plasma to brain and muscle concentrations were close to 1 for all tissues measured.
Specifically, in Study 9 following oral dosing of risdiplam at 3 mg/kg/ day for 7 days in monkeys (n = 2), total plasma concentrations (794 ng/mL) matched those in brain (783 ng/g) and muscle (668 ng/g), whereas CSF drug level (53.5 ng/mL) were within the same range of the calculated free compound concentration in plasma (119 ng/mL) ( Figures 1C and 2 ).
The time-course of risdiplam concentrations in tissue and plasma is shown for adult rats ( Figure 3A ,B) and adult FVB mice ( Figure 3C , D). Parallel time courses of drug levels were measured in plasma, brain, CSF, and muscle, up to 48 hours after the last dose, confirming a parallel elimination in those tissues (Study 7, Figure 3A) . A similar decreasing trend, with plasma and brain levels decreasing in parallel, was confirmed after 28 days of daily dosing in rats (Figure 3B ) and after single PO or IP dose in mice ( Figure 3C,D) . Absolute levels of risdiplam in rat brain were in the same range as total plasma levels in both Figure 3A ,B. Brain levels were slightly higher or slightly lower than plasma depending on interexperimental variability ( Figure 3A,B) . This is also quite apparent in Figure 1A where the symbols for rats (triangles) are on either side of the unity line. In rats dosed at 7.5 mg/kg/day PO (Study 8), brain-to-total-plasma ratios after 90 days of dosing were close to 1 (0.92 average for n = 13), and drug levels in plasma and brain samples were BLQ after a further 8 weeks of recovery treatment-free period (n = 6).
Radioactivity was rapidly and widely distributed following oral administration of first sampling point). Concentrations of radioactivity declined over the duration of the study in plasma and tissues. Tissue/plasma ratios of radioactivity were high in the bone marrow (5.5), kidney cortex (9.1), kidney medulla (4.1), liver (7.2), lung (7.1), heart (2.4), pancreas (4.7), spleen (8.0), trachea (2.7), mucosa of small intestine (3.4), large intestine (1.5), and rectum (4.1) 2 hours after oral administration. Tissue/plasma ratios 10 minutes after IV administration were similar to the oral 2-hour ratios in all tissues including intestinal mucosa.
In a tissue distribution study in two cynomolgus monkeys, muscle, brain, heart, and larynx drug levels were all within the total plasma concentration, with less than 30% difference (Study 9, Figure 2 ). Bone marrow and spleen showed a high interindividual variability, with tissue/plasma ratio around 5. Tissue/plasma ratios were higher for kidney (10) , liver and duodenum (both 33). In the same study, two other monkeys were killed 6 weeks after the last dose, and drug levels in plasma, CSF, muscle, brain, heart, and bone marrow were all BLQ. Risdiplam concentrations in duodenum, spleen, and larynx were below 1 ng/g and around 4 ng/g in both liver and kidney.
Similar tissue distribution studies in rat and monkeys, and rat QWBA were also performed using RG7800. Following oral administration, RG7800 widely distributed and was present in key tissues and organs affected in SMA (brain, muscle, bone, mucosa of the GI tract, pancreas, liver, lung, heart, kidney, and spleen) at concentrations equal to or higher than total plasma.
| SMN protein increase in CNS and periphery
Several PD studies investigated the effect of orally administered small molecule SMN2 splicing modifiers on SMN protein levels in key target Both risdiplam and RG7800 show high passive permeability, which is important for GI and tissue uptake, and are not MDR1 substrates in humans, which would otherwise restrict brain distribution. 25 In rat pKp,uu was estimated at 0.33 based on rodent Mdr1a ER, which is in line with the observed in vivo Kp,uu of 0.28, confirming Mdr1a as the principal mechanism lowering rat CSF levels (Figure 1C ) and mice brain levels ( Figure 1A) . Still, this property did not limit SMN protein increase in mouse brain. Risdiplam is also a strong 14, 16, 29 These molecules, including risdiplam, not only improved survival, body weight, phenotype, and motor behavior in different mouse models of SMA but also prevented motor neuron loss and rescued synaptic pathology in mice. 14, 16, 17 These preclinical data indicate that, based on the same mechanistic rational, risdiplam should also distribute into the CNS in patients with SMA after oral administration (of an oral solution): thus, this is expected to lead to functional SMN protein level increases in the CNS and preservation of lower alpha motor neurons.
Denervation and atrophy of skeletal muscles, as well as intrinsic abnormalities in SMA skeletal muscle cells, are thought to contribute directly to SMA disease pathogenesis. 6, 12 The free drug hypothesis applies to all tissues and unbound drug in plasma is also expected to be in equilibrium with free drug in the muscles. In this study, we
show that risdiplam distribution to, and elimination from, muscle tissue correlates with plasma levels in mice, rats, and monkeys. Importantly, this profile is independent of dose, duration of dosing or species. We also demonstrated that SMN protein levels increased in plasma levels in bone, mucosa of the GI tract, pancreas, liver, lung, heart, kidney, and spleen were therefore confirmed in rodents and nonhuman primates. Those tissues have been specifically described as affected in SMA, beyond the CNS and muscle. 5, 6 We also show here that RG7800 distributed widely in C/C-allele mice and led to increased SMN protein levels in other key organs affected in SMA in addition to an increase in blood, CNS, and muscle ( Figure 6 As an orally administered product, risdiplam increases functional SMN protein levels in both the CNS and peripheral tissues in animal models and it is also expected to do so in patients based on the same mechanistic rational. This may be more beneficial than a therapeutic agent solely targeting the motor neurons of the spinal cord.
In mouse models of SMA, a 100% or greater increase in brain SMN levels above vehicle results in near-normal phenotype. 29 Here we demonstrate that, in mouse models of SMA treated with oral small molecule SMN2 splicing modifiers including risdiplam, the percentage increase in SMN protein in peripheral blood (and muscle and other tissues) correlates with that in the CNS (Figures 4-7) . This indicates that a change in SMN protein in blood could be used as a surrogate, or biomarker to monitor increases of SMN protein levels in the CNS. Another important advantage of risdiplam is the durability of the effect. As we have shown in this current work, protein levels follow compound exposure in plasma and tissues and will stay elevated (relative to the untreated control) as long as the drug is administered, without attenuation of the effect. As SMA is a chronic progressive disease, this persistent upregulation of functional SMN protein levels in all organs and tissues is expected to result in durable benefit to the patient.
In conclusion, this study demonstrates that risdiplam distributes well into the CNS and peripheral tissues, including muscle, blood, and brain, of mice, rats, and monkeys following single or repeated 
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